Nephrotic Syndrome
102
20
24
49
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
6 terminated out of 102 trials
89.1%
+2.6% vs benchmark
25%
25 trials in Phase 3/4
10%
5 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (102)
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Effects of Meal Macronutrients on Postprandial Lipids
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Immune System Related Kidney Disease
Belimumab With Rituximab for Primary Membranous Nephropathy
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
Multitarget Strategy for Primary Podocytopathies
Atacicept in Multiple Glomerular Diseases
Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Diuretic Tuner Clinical Decision Support
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome
The Selection of Initial Treatment Regimens for Adolescent Nephrotic Syndrome.
Effectiveness of Educational Gamified Cards About Nephrotic Syndrome